Investors are taking a fresh look at Hemostemix Inc, and it’s showing in the stock price.
Hemostemix Inc (HEM.V) saw its stock rise to CA$0.07 yesterday, marking a 15.38% increase. This jump comes as the company works to secure funding through private placements, signaling that investors are confident in its future.
Investor takeaway: The recent price increase indicates positive sentiment among investors, likely driven by Hemostemix's strategic efforts to strengthen its capital base.
Advertisement
Hemostemix Inc
HEM.V
HEM.V
Hemostemix Inc
WealthAwesomeAdvertisement
Market cap
$13.32M
52W high
$0.14
52W low
$0.04
1W change
+15.38%
Beta
0.61
Analyst Price Targets
Based on analyst covering HEM
Wall Street analysts forecast HEM stock price to rise 1180.0% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$0.96
+1180.0% Upside
Current Price
C$0.07
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Advertisement
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on HEM's historical volatility
30-Day Vol
140.1%
Annualized
90-Day Vol
116.5%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$0.09
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$0.08 | C$0.05 – C$0.13 |
| 60 trading days | C$0.08 | C$0.04 – C$0.17 |
| 90 trading days | C$0.09 | C$0.04 – C$0.21 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
15.38% Surge in Stock Price
Hemostemix Inc's stock price climbed to CA$0.07, reflecting increased investor interest and confidence in the company's future.
Bull case
With the successful completion of several private placements, Hemostemix is set to improve its operational capabilities and advance its innovative therapies. This could lead to significant growth for the company.
Bear case
Despite the recent surge, Hemostemix is still a small-cap company, which comes with its own risks. Market volatility and reliance on successful product development are factors to consider.
Recent Funding Initiatives
Advertisement
Hemostemix has been actively closing private placements to raise capital, with the latest round bringing in CA$322,250. This funding is vital as the company aims to advance its VesCell therapy, which has the potential to revolutionize regenerative medicine.
Market Reaction
The stock's impressive gain reflects a broader market optimism about Hemostemix's future. Investors seem to be betting on the company's ability to use its recent funding to drive growth and innovation in the healthcare sector.
Looking Ahead
As Hemostemix continues to secure funding and develop its product pipeline, investors will be keeping a close eye on updates regarding clinical trials and market entry strategies. The company's ability to execute its plans will be crucial in maintaining this momentum.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
